Pub-2014

Articles

Title
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom's macroglobulinemia
Survival Trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Waldenstrom Macroglobulinemia
Waldenström macroglobulinemia: genetics dictates clinical course